| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Pyrrole-2-carboxaldehyde is a weak inhibitor of tyrosinase, an enzyme involved in melanin production. Tyrosinase is a copper-containing oxidase that catalyzes the rate-limiting steps in melanin biosynthesis. As a weak inhibitor, it may have applications in biochemical experiments and drug synthesis. The compound is not known to have other specific biological targets.
|
|---|---|
| ln Vitro |
As a weak tyrosinase inhibitor, pyrrole-2-carboxaldehyde can be used to study melanin production and related pathways in vitro. It is also used as a pharmaceutical intermediate and a key starting material for the preparation of pyrrole-2-carboxylic acid by oxidation reaction. The compound has been used to develop a fluorescent nanoparticle probe for detecting Pseudomonas aeruginosa, and its Schiff bases have been characterized as novel antioxidants.
|
| ln Vivo |
Pyrrole-2-carboxaldehyde is not a pharmacologically active drug and does not exhibit established in vivo therapeutic activity. Its primary use is as a chemical intermediate and research reagent in organic synthesis and biochemical experiments. It is not administered to animals in pharmacological studies and has no known physiological effects.
|
| Enzyme Assay |
In vitro assays for pyrrole-2-carboxaldehyde are not standard, as it is primarily a chemical intermediate. For tyrosinase inhibition studies, a standard protocol involves incubating the enzyme with a substrate (e.g., L-DOPA) in the presence of varying concentrations of the compound (typically 1-100 µM) and measuring the production of dopachrome spectrophotometrically at 475 nm. IC₅₀ values are calculated from dose-response curves. For quality control, the compound is characterized by NMR, HPLC, and melting point determination.
|
| Cell Assay |
Cell-based experiments are not performed with pyrrole-2-carboxaldehyde as a test compound for biological activity. When used to synthesize drug candidates, those products may be tested in cell culture using standard protocols. The intermediate itself is not evaluated in cellular systems. Its role is strictly chemical—serving as a building block for the synthesis of biologically active molecules.
|
| Animal Protocol |
In vivo animal studies are not conducted with pyrrole-2-carboxaldehyde, as it is a research reagent for chemical synthesis. When used to synthesize drug candidates, those final products undergo standard preclinical evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of pyrrole-2-carboxaldehyde are not characterized, as it is not a drug substance. Based on its physicochemical properties (molecular weight 95.1, soluble in DMSO at 80 mg/mL), the compound would be expected to have moderate bioavailability if administered. However, it is not intended for human exposure.
|
| Toxicity/Toxicokinetics |
Pyrrole-2-carboxaldehyde is a combustible solid and may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from light and moisture, preferably at -20°C for long-term storage.
|
| References | |
| Additional Infomation |
Pyrrole-2-carboxaldehyde is a pyrrole derivative with a formyl group substituent at the 2-position. It belongs to the pyrrole class of compounds and is also a 1,3-thiazolyl-2-carboxaldehyde class. Pyrrole-2-carboxaldehyde has been reported in capparis spinosa, tobacco (Nicotiana tabacum), and other organisms with relevant data.
Pyrrole-2-carboxaldehyde is a versatile intermediate used in pharmaceutical synthesis, natural product chemistry, and heterocyclic compound preparation. Its Schiff bases have been studied for antioxidant activity. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—serving as a reactive aldehyde and pyrrole building block. |
| Molecular Formula |
C5H5NO
|
|---|---|
| Molecular Weight |
95.10
|
| Exact Mass |
95.037
|
| CAS # |
1003-29-8
|
| PubChem CID |
13854
|
| Appearance |
White to light brown solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
219.1±13.0 °C at 760 mmHg
|
| Melting Point |
50 - 51 °C
|
| Flash Point |
106.7±0.0 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
0.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
7
|
| Complexity |
72.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C([H])C1=C([H])C([H])=C([H])N1[H]
|
| InChi Key |
ZSKGQVFRTSEPJT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5NO/c7-4-5-2-1-3-6-5/h1-4,6H
|
| Chemical Name |
1H-pyrrole-2-carbaldehyde
|
| Synonyms |
Pyrrole-2-carboxaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (1051.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.5152 mL | 52.5762 mL | 105.1525 mL | |
| 5 mM | 2.1030 mL | 10.5152 mL | 21.0305 mL | |
| 10 mM | 1.0515 mL | 5.2576 mL | 10.5152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
